An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity

Overview

Journal Vaccines (Basel)

Date 2024 Jun 27

PMID 38932404

Authors

Emma Chang-Rabley

Menno C van Zelm

Emily E Ricotta

Emily S J Edwards

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2 pandemic has heightened concerns about immunological protection, especially for individuals with inborn errors of immunity (IEI). While COVID-19 vaccines elicit strong immune responses in healthy individuals, their effectiveness in IEI patients remains unclear, particularly against new viral variants and vaccine formulations. This uncertainty has led to anxiety, prolonged self-isolation, and repeated vaccinations with uncertain benefits among IEI patients. Despite some level of immune response from vaccination, the definition of protective immunity in IEI individuals is still unknown. Given their susceptibility to severe COVID-19, strategies such as immunoglobulin replacement therapy (IgRT) and monoclonal antibodies have been employed to provide passive immunity, and protection against both current and emerging variants. This review examines the efficacy of COVID-19 vaccines and antibody-based therapies in IEI patients, their capacity to recognize viral variants, and the necessary advances required for the ongoing protection of people with IEIs.

Citing Articles

SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.

Alhamlan F, Al-Qahtani A Int J Mol Sci. 2025; 26(3).

PMID: 39941026 PMC: 11818319. DOI: 10.3390/ijms26031263.

References

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

Farcet M, Karbiener M, Knotzer S, Schwaiger J, Kreil T . Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe. J Infect Dis. 2022; 226(8):1396-1400. PMC: 9494343. DOI: 10.1093/infdis/jiac358. View

Chiu S, Chan K, Chu K, Kwan S, Guan Y, Poon L . Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005; 40(12):1721-9. PMC: 7107956. DOI: 10.1086/430301. View

Barouch D, Stephenson K, Sadoff J, Yu J, Chang A, Gebre M . Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. N Engl J Med. 2021; 385(10):951-953. PMC: 8314733. DOI: 10.1056/NEJMc2108829. View

Tangye S . Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol. 2022; 151(4):818-831. PMC: 9746792. DOI: 10.1016/j.jaci.2022.11.010. View

Stinca S, Barnes T, Vogel P, Meyers W, Schulte-Pelkum J, Filchtinski D . Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches. PLoS One. 2021; 16(11):e0259731. PMC: 8629175. DOI: 10.1371/journal.pone.0259731. View

Orange J, Hossny E, Weiler C, Ballow M, Berger M, Bonilla F . Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006; 117(4 Suppl):S525-53. DOI: 10.1016/j.jaci.2006.01.015. View

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

10.

Giardino G, Milito C, Lougaris V, Punziano A, Carrabba M, Cinetto F . The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet). J Clin Immunol. 2022; 42(5):935-946. PMC: 9020753. DOI: 10.1007/s10875-022-01264-y. View

11.

Totschnig D, Augustin M, Niculescu I, Laferl H, Jansen-Skoupy S, Lehmann C . SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience. Viruses. 2022; 14(10). PMC: 9607212. DOI: 10.3390/v14102278. View

12.

Hartley G, Edwards E, Bosco J, Ojaimi S, Stirling R, Cameron P . Influenza-specific IgG1 memory B-cell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clin Transl Immunology. 2020; 9(10):e1199. PMC: 7563650. DOI: 10.1002/cti2.1199. View

13.

Cao Y, Jian F, Yu Y, Song W, Yisimayi A, Wang J . Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022; 614(7948):521-529. PMC: 9931576. DOI: 10.1038/s41586-022-05644-7. View

14.

Schwaiger J, Karbiener M, Aberham C, Farcet M, Kreil T . No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic. J Infect Dis. 2020; 222(12):1960-1964. PMC: 7546122. DOI: 10.1093/infdis/jiaa593. View

15.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

16.

Diez J, Romero C, Gajardo R . Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy. 2020; 12(8):571-576. PMC: 7222542. DOI: 10.2217/imt-2020-0095. View

17.

Wilkinson S, Richter A, Casey A, Osman H, Mirza J, Stockton J . Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol. 2022; 8(2):veac050. PMC: 9384748. DOI: 10.1093/ve/veac050. View

18.

Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T . Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022; 219(8). PMC: 9206114. DOI: 10.1084/jem.20220131. View

19.

Yue C, Song W, Wang L, Jian F, Chen X, Gao F . ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023; 23(3):278-280. PMC: 9897732. DOI: 10.1016/S1473-3099(23)00010-5. View

20.

Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L . Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome. J Clin Immunol. 2022; 42(3):471-483. PMC: 8798309. DOI: 10.1007/s10875-022-01215-7. View